Venturi mask market seen reaching $6.13 billion by 2030

The venturi mask market is projected to grow from $4.08 billion in 2025 to $6.13 billion by 2030, driven by rising respiratory disease rates, wider oxygen therapy use and expanding healthcare infrastructure. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Venturi masks deliver a fixed oxygen concentration, which matters for patients who need precise oxygen control, especially people with COPD and other chronic respiratory conditions. - Rising demand for respiratory care equipment is tied to the growing burden of chronic lung disease and the expansion of hospital and home-based oxygen therapy.

What happened: - The Business Research Company released a market study on the global venturi mask market on September 3, 2026. - The study projects the market will rise from $4.08 billion in 2025 to $4.43 billion in 2026. - The report forecasts the market will reach $6.13 billion by 2030. - The report expects the market to grow at an 8.5% compound annual growth rate from 2025 through 2030.

The details: - The historical growth outlook is linked to higher respiratory illness rates, more critical care units in hospitals, broader use of oxygen therapy, better availability of respiratory care equipment and expanded emergency medical services. - The forecast period is supported by rising demand for home-based oxygen therapy, an aging population with chronic respiratory conditions, growth in ambulatory respiratory care services, greater focus on infection control and wider adoption in emerging healthcare markets. - Key trends include stronger demand for accurate oxygen delivery systems, wider use of disposable venturi masks, broader use in COPD management, continued development of hospital respiratory infrastructure and more attention to infection prevention in device design. - A venturi mask uses the venturi principle to mix oxygen with ambient air through a narrow nozzle and deliver a controlled oxygen concentration. - The device is designed for patients who need tightly regulated oxygen levels so respiratory drive is not disrupted. - The report says North America was the largest venturi mask market in 2025. - The report expects Asia-Pacific to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - More information is available in the full report. - A free sample is available here.

Between the lines: - The forecast points to sustained demand for devices that can deliver oxygen more precisely as respiratory disease prevalence rises. - The regional split suggests mature markets are still large, but future growth is likely to come from expanding healthcare access in Asia-Pacific and other emerging regions. - The report cites a December 2023 National Library of Medicine projection that global COPD cases among people age 25 and older could approach 600 million by 2050, up 23% from 2020. - The same projection said female COPD cases could rise 47.1%, compared with 9.4% for males, and that low- and middle-income regions may carry more than twice the caseload of high-income regions.

What's next: - Market growth is expected to continue as hospitals, ambulatory care providers and home-care systems expand respiratory treatment capacity. - Disposable masks, infection-control features and more precise oxygen delivery systems are likely to remain focal points for product development. - Emerging healthcare markets are expected to add to future demand as access to respiratory care equipment improves.

The bottom line: - Venturi masks are a niche but growing respiratory device category, and the market’s expansion is being driven by the same forces reshaping global respiratory care: more chronic disease, more oxygen therapy and a stronger focus on precision and infection control.